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ABSTRACT
Introduction Liver cirrhosis is a growing global 
healthcare challenge. Cirrhosis is characterised by severe 
liver fibrosis, organ dysfunction and complications related 
to portal hypertension. There are no licensed antifibrotic 
or proregenerative medicines and liver transplantation 
is a scarce resource. Hepatic macrophages can promote 
both liver fibrogenesis and fibrosis regression. The safety 
and feasibility of peripheral infusion of ex vivo matured 
autologous monocyte- derived macrophages in patients 
with compensated cirrhosis has been demonstrated.
Methods and analysis The efficacy of autologous 
macrophage therapy, compared with standard medical 
care, will be investigated in a cohort of adult patients 
with compensated cirrhosis in a multicentre, open- label, 
parallel- group, phase 2, randomised controlled trial. The 
primary outcome is the change in Model for End- Stage 
Liver Disease score at 90 days. The trial will provide the 
first high- quality examination of the efficacy of autologous 
macrophage therapy in improving liver function, non- 
invasive fibrosis markers and other clinical outcomes in 
patients with compensated cirrhosis.
Ethics and dissemination The trial will be conducted 
according to the ethical principles of the Declaration 
of Helsinki 2013 and has been approved by Scotland 
A Research Ethics Committee (reference 15/SS/0121), 
National Health Service Lothian Research and 
Development department and the Medicine and Health 
Care Regulatory Agency- UK. Final results will be presented 
in peer- reviewed journals and at relevant conferences.
Trial registration numbers ISRCTN10368050 and 
EudraCT; reference 2015- 000963- 15
INTRODUCTION
Liver disease is responsible for almost 
2 million deaths per year globally, 1 million 
directly relating to complications of end- 
stage liver failure and a further 1 million 
due complications of hepatitis including 
hepatocellular carcinoma (HCC).1 Cirrhosis 
and liver cancer are now, respectively, the 
11th and 16th most common cause of death 
globally, accounting for 3.5% of all deaths. 
Variation in liver disease epidemiology occurs 
relative to the prevalence of modifiable risk 
factors including harmful alcohol ingestion, 
obesity/metabolic syndrome and viral hepa-
titis.2 Worldwide there were 10·6 million prev-
alent cases of decompensated cirrhosis and 
112 million prevalent cases of compensated 
cirrhosis in 2017.3
Cirrhosis represents the end- stage of 
chronic liver injury and progressive fibrosis 
(scarring), irrespective of the underlying 
aetiology. It is characterised by severe liver 
fibrosis leading to architectural disruption, 
hepatocyte dysfunction and portal hyper-
tension. Cirrhosis typically affects those of 
working age, which has broad socioeconomic 
impacts. Furthermore, cirrhosis impairs 
health- related quality of life (HRQoL) 
including mental health and physical factors 
and reduced ability to perform activities of 
Strengths and limitations of this study
 ► First randomised controlled trial of an innovative 
cell- based therapy for cirrhosis.
 ► Range of evidence- based non- invasive assess-
ments of liver fibrosis and function.
 ► Concurrent longitudinal measurement of health- 
related quality of life in an important chronic liver 
disease population.
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daily living4; those with primary biliary cholangitis (PBC), 
non- alcoholic fatty liver disease (NAFLD) and hepatitis C 
virus (HCV) appear disproportionately affected.5
The classical dichotomy of chronic liver disease staging 
is compensated (asymptomatic) or decompensated 
cirrhosis. Acute decompensation delineates the devel-
opment of one or more associated sequelae and is a key 
prognostic inflection point. The transition from compen-
sated to decompensated cirrhosis occurs at a rate of about 
5%–7% per year.6 Decompensation represents a prog-
nostic milestone as it significantly alters mortality, with a 
cumulative 1- year mortality of 77% for those with stage 
3 and 4 decompensated disease vs 4.4% in those with 
compensated disease. Importantly, emergency hospital-
isation for decompensated liver disease heralds a deteri-
oration in a patient’s prognosis independent of stage of 
cirrhosis.7
Cirrhosis decompensation heralds the development of 
widespread organ dysregulation, including portal hyper-
tension, splanchnic vasodilation, left ventricular impair-
ment and systemic immune dysfunction. Inflammatory 
mediators of liver disease may underpin and potentiate 
nitric oxide- mediated capillary dysfunction, direct immu-
nocytopathy and induce significant metabolic derange-
ment and redistribution of essential nutrient precursors.8
For patients in whom disease- specific therapy is unsuc-
cessful or not possible, treatment options remain limited. 
Presently, although numerous agents have been evalu-
ated in clinical trials, there are no approved pharmaco-
logical therapies for reversing fibrosis or stimulating liver 
regeneration in the cirrhotic liver.9 Liver transplantation 
remains the only curative option for those with end- stage 
cirrhosis or HCC. Unfortunately, a significant proportion 
of those referred for transplant assessment are ineligible 
and ~12% die annually while on the waiting list in the 
UK.10 11 Those who do undergo liver transplantation 
require lifelong immunosuppression with inherent risks 
of toxicity and adverse effects.12
Although whole organ or split liver transplantation 
are well established procedures to reinstate liver func-
tional capacity, cell- based transplantation approaches are 
emerging.13 Successful cell therapy could theoretically 
overcome organ availability limitations, while avoiding 
invasive surgical interventions. Successful hepatocyte 
transplantation involves reconstitution of as little as 
1%–2.5% of functional tissue across a range of inherited 
metabolic liver diseases and highlights the utility of such 
approaches.14 Furthermore, there is a requirement for 
treatments that can ‘bridge’ patients with cirrhosis until 
a donor organ is available or allow spontaneous regener-
ation to occur following acute liver failure. Cell therapies 
that sufficiently modulate cirrhosis by reducing fibrosis 
and stimulating liver function may also promote endog-
enous tissue repair and regeneration such that the need 
for transplantation is delayed or obviated.
Previous studies have typically focused on the use of 
mesenchymal stem cells (MSCs), hepatocyte stem cells 
and heterogeneous cell populations which will include 
proinflammatory and profibrotic cell lineages. Despite 
promising preclinical studies, randomised controlled 
trials (RCTs) of autologous cell therapies in cirrhosis have 
so far been disappointing.15 16
Macrophages are a heterogeneous, highly plastic popu-
lation of cells with a diverse spectrum of roles within the 
liver including phagocytosis and maintenance of immune 
tolerance. Hepatic monocyte- derived macrophages are 
known to play a dual role in liver fibrosis. During chronic 
liver injury models they mediate the recruitment of proin-
flammatory cells and activation of hepatic stellate cells to 
promote fibrogenesis.14 Conversely, fibrosis regression is 
characterised by an in situ phenotypic switch to a restor-
ative hepatic macrophage population with pro- resolution 
properties17 whereby liver repair and regeneration is 
facilitated by increased expression of matrix metallopro-
teinases (MMPs), growth factors and phagocytosis- related 
genes.18 19 This process of phenotypic ‘switching’ from 
a proinflammatory ‘M1- like’ moiety, to a pro- resolution 
‘M2- like’ macrophage is mediated via down- regulation 
of NOD- containing, LRR- containing and pyrin domain- 
containing protein 3.14
In a mouse model of chronic liver injury, cell therapy 
with unmanipulated syngenic macrophages reduced 
fibrosis and improved markers of liver function.20 Further-
more, infusion of human macrophages (differentiated 
from cirrhotic patients’ apheresis- derived CD14+ mono-
cytes) also resolved liver fibrosis in mice, indicating their 
suitability for clinical therapy.18 20 21
We recently demonstrated the feasibility of performing 
apheresis in cirrhotic patients and differentiating autol-
ogous bone marrow derived monocytes into macro-
phages.22 This process includes specific CD14+ monocyte 
isolation from peripheral circulation leucopharesis 
collections using CliniMACS automated separation 
device, a closed system, where the product is incubated 
with CD14 labelled magnetic beads, allowing separation 
of CD14+ cells when passed over a magnetic column. 
Selected CD14+ monocytes are counted and resuspended 
in differentiation medium containing 100 ng/mL macro-
phage colony- stimulating factor (M- CSF). Cells are 
placed into closed system, low adhesion culture bags at 
optimum cell density (2×106 cells per mL and per cm3). 
Cells are cultured in a humidified atmosphere at 37°C, 
with 5% CO2, for 7 days. Media replenishment is under-
taken twice during culture (typically days 3 and 5), using 
differentiation media supplemented with 100 ng/mL 
M- CSF. Flow cytometry is used to determine cell viability 
and phenotype cell populations premonocyte and post-
monocyte selection and postmacrophage differentiation 
prior to product release, this has been validated for 7- day 
and 10- day time points.
We also have extensive preclinical data demonstrating 
that peripherally injected macrophages hone to the 
liver (predominantly) and spleen (after passing rapidly 
through the lungs) and that this process in enhanced 
in the presence of liver damage.20 23 Furthermore, in a 
first- in- human study we confirmed the safety, feasibility 
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and maximum achievable dose of autologous macro-
phages.24 The study was not controlled, and therefore, 
unable to evaluate efficacy. However, we observed some 
initial signals related to enhanced fibrosis remodelling 
and liver function that warranted assessment in an RCT 
as presented here.
Objectives
The primary objective of this phase 2 RCT is to evaluate 
whether there is an improvement in liver function at 3 
months in patients receiving autologous macrophage 
therapy compared with standard medical care.
The secondary objectives are to assess any improve-
ment in markers of liver fibrosis, increased disease related 
quality of life, reduced liver related clinical events and 
prolonged transplant- free survival.
Trial design
The MATCH trial is designed as a multicentre, open- 
label, parallel- group, phase 2, RCT to compare autolo-
gous macrophage therapy with standard medical care in 
patients with compensated cirrhosis. Randomisation will 
be performed with a 1:1 allocation ratio and the primary 
outcome is the baseline to 90- day change in Model 
for End- Stage Liver Disease (MELD) score. Figure 1 
provides an overview of trial pathway following rando-
misation to the respective arms. Initially, the proposed 
trial was designed to administer three infusions to those 
randomised to the treatment arm. It became apparent 
that it would not be acceptable or feasible to continue 
with three infusions due to the onerous commitment 
required of participants and the challenge to complete 
the trial within the proposed time frame. Therefore, as a 
pragmatic approach, and in line with the phase 1 study, 
it was decided that a single infusion protocol should be 
adopted to simplify the participant journey and ensure 
adequate recruitment. This was agreed with the trial 




The MATCH 0.1 trial is an investigator- led study, funded 
by the Medical Research Council (reference MR/
M007588/1) and sponsored by ACCORD (Academic and 
Clinical Central Office for Research and Development 
for National Health Service (NHS) Lothian/University of 
Edinburgh). Trial oversight is also provided by a TSC and 
DMC, who are impartial around aspects of study design 
and logistics but provide independent advice and interval 
safety analyses. The study started initially in 2016 and is 
likely to continue until late 2022. All study- related docu-
ments were designed by the trial team with input from 
ACCORD, an independent statistician and the Scottish 
National Blood Transfusion Service (SNBTS) team. The 
trial will be conducted according to the ethical principles 
of the Declaration of Helsinki 2013 and has been approved 
by Scotland A Research Ethics Committee (reference 
15/SS/0121), NHS Lothian Research and Development 
department and the Medicine and Health Care Regula-
tory Agency (MHRA- UK). Good Clinical Practice regula-
tions will be followed and written informed consent will 
be obtained from all participants.
Study setting
The MAcrophage Therapy for iver CirrHosis (MATCH) 
trial is recruiting in three hepatology centres in Scot-
land: Royal Infirmary of Edinburgh (Tertiary Transplant 
Centre/level 3 hepatology services), Ninewells Hospital, 
Dundee and Glasgow Royal Infirmary (both level 2 hepa-
tology centres). There are plans to potentially extend 
recruitment to include additional sites.
Patient and public involvement
There was no direct patient or public involvement groups 
involved in the study design. The overall study design was 
developed from previous experience of the investigators 
involved in the design and coordination of similar studies.
ELIGIBILITY CRITERIA (INCLUSIONS/EXCLUSIONS)
Inclusion criteria
 ► Aged between 18 and 75 years (inclusive) at time of 
screening
 ► Aetiology: One or more of:
 – Alcohol- related liver disease (no active alcohol 
misuse ≥6 calendar months prior to screening). 
Figure 1 Schematic of trial timeline.
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Features of chronic liver disease with a compatible 
history of alcohol excess (>80 g/day), in the ab-
sence of other causes of chronic liver disease.
 – PBC 2 out of: Cholestatic liver function tests (LFTs), 
Positive antimitochondrial antibody (titre >1:40). 
Compatible liver histology (if already receiving ur-
sodeoxycholic acid must be established on current 
dose >3 months prior to enrolment).
 – NAFLD Either: Histological evidence of hepatic 
steatosis in the absence of other liver diseases Or: 
Imaging compatible with NAFLD (eg, fatty infil-
tration of liver) and one or more risk factors (eg, 
elevated body mass index, type 2 diabetes mellitus, 
hypertriglyceridaemia, hypertension) and the ab-
sence of significant alcohol consumption (<20 g/
day) and no evidence of other causes of chronic 
liver disease.
 – Cryptogenic cirrhosis diagnosis of cirrhosis unat-
tributable to any other cause.
 – Haemochromatosis diagnosis made on basis of 
compatible biochemistry (transferrin saturation 
>60%, ferritin >400), genotype (homozygous 
C282Y or H63D compound heterozygote) or 
histology.
 – Alpha- 1 antitrypsin deficiency diagnosis based on 
compatible genetic, phenotypic or histological 
testing.
 – Previous chronic hepatitis C (sustained viral re-
sponse ie, undetectable HCV RNA 24 weeks after 
treatment).
 ► Diagnosis of cirrhosis—invasive or non- invasive 
criteria cirrhosis defined as any of:
 – Biopsy- confirmed diagnosis of cirrhosis.
 – Transient elastography (TE)—≥15 kPa.
 – Clinical and radiological features which in the 
opinion of the investigator correlate with a diagno-
sis of cirrhosis.
 ► A MELD score (Pre- 2016) of ≥10 and ≤17 at screening 
visit.
Exclusion criteria
Refusal or inability to give written informed consent to 
participate in the study.
 ► Other causes of chronic liver disease/cirrhosis not 
included in the listed aetiologies
 ► Portal hypertensive haemorrhage; active episode of 
bleeding requiring hospitalisation in the last 3 months 
where varices have not been eradicated by endoscopic 
band ligation or transjugular intrahepatic portosys-
temic shunts (TIPSS).
 ► Ascites unless, in the opinion of the investigator, 
is minimal and well controlled with no increase to 
diuretic therapy in the last 3 months.
 ► Hepatic encephalopathy; current or requiring hospi-
talisation for treatment in the last 3 months.
 ► HCC—uncertain cases to be discussed at the local 
hepatobiliary multidisciplinary team meeting. 
Dysplastic or indeterminate nodules to be excluded; 
regenerative or other nodules to be included at discre-
tion of investigator.
 ► Previous diagnosis of HCC.
 ► Previous organ transplant recipient.
 ► Listed for liver transplantation.
 ► Any situation that in the investigators opinion may 
interfere with optimal study participation such as 
alcohol or drug abuse, domicile too distant from 
study site, potential non- compliance or inability to 
cooperate.
 ► Presence of clinically relevant acute illness which may 
preclude on basis of safety.
 ► Presence or history of cancer with exception of 
adequately treated localised skin carcinoma, in situ 
cervical cancer or solid malignancy excised in total, 
with no recurrence (5- year interval).
 ► Pregnancy or breast feeding.
Interventions
Participants who are randomised to the treatment arm 
will receive an infusion of the maximum achieved dose up 
to 1×109 (day 0). The apheresis product will be collected 
under the terms of the Human Tissue (Quality and Safety 
for Human Application) Regulations 2007 No. 1523 
enacting the requirements of the EU Tissues and cells 
Directive (2004/2023) and associated Commission Direc-
tives at the Apheresis Unit (Royal Infirmary of Edinburgh, 
Edinburgh, UK). CD14+ monocytes will be isolated, and 
the macrophage cell product will be manufactured as 
previously described,25 in compliance with GMP regula-
tions under the terms of the SNBTS MIA (IMP) licence 
at the SNBTS Cell Therapy Facility (Scottish Centre for 
Regenerative Medicine, Edinburgh, UK).
Each patient will be monitored closely during the infu-
sion to identify potential hypersensitivity reactions and 
4 hours postinfusion bloods to monitor for any evidence 
of macrophage activation syndrom. A total of 28 partici-
pants will be randomised to standard medical care and 28 
to receive the cell infusion, allowing for original estimate 
of 5 dropouts from each arm. Additional safety data will 
be collected for the first infusion only for the first three 
patients randomised to the treatment arm. If it has not 
been possible to achieve 1×109 macrophages, then the 
participants will be infused with the quantity obtained, 
with minimum concentration being 1.25×108 cells. This 
minimum cell concentration was derived from previous 
validation work and is stipulated as part of the product 
release criteria as designated by the MHRA.
Outcomes
Primary outcome measure
Model of End-Stage Liver Disease
The MELD was originally devised to predict survival 
in patients with complications of portal hypertension 
undergoing elective placement of TIPSS. The algorithm 
is based on: creatinine, bilirubin and prothrombin ratio 
and has been demonstrated to be superior to the Child- 
Turcotte- Pugh score in predicting 3- month mortality 
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among patients with end- stage liver disease.26 However, 
the MELD score has also been applied to predict survival 
in patients with cirrhosis with infections, variceal haemor-




The number of participants in each of the two treat-
ment arms who are transplant free at 12 months will be 
expressed as proportions and a binomial test will be used 
for the comparison of proportions between the treatment 
arm and the control arm. The difference in proportions 
will be presented along with the 95% CI for the differ-
ence in the proportions.
The time to death or transplant will be presented using 
a Kaplan- Meier survival curve stratified by treatment and 
accompanied by a log- rank statistic comparing the two 
arms. Survival estimates with be presented by treatment 
arm at 3, 6, 9 and 12 months.
Non-invasive markers of fibrosis
Changes in our secondary outcome measures over 90 
days up to maximal 360 days as per schedule (table 1), 
these include: serum enhanced liver fibrosis (ELF) test 
(iQur, London, UK, serum Protein Fingerprint markers 
(Nordic Bioscience, Herlev, Denmark), hepatic TE 
(Echosens, Paris, France) and the UK End- Stage Liver 
Disease (UKELD) score.
Enhanced liver fibrosis
A standardised clinically validated immunoassay test 
measuring three serum biomarkers which have been 
shown to correlate to the level of liver fibrosis assessed by 
liver biopsy, comprising:
 ► Hyaluronic acid.
 ► Tissue Inhibitor of Metalloproteinase 1.
 ► Aminoterminal propeptide of type III procollagen.
The concentrations of each individual protein 
marker are combined in an algorithm which produces a 
composite score related to the level of liver fibrosis. The 
ELF score is a sensitive, specific and validated method for 
the non- invasive assessment of hepatic fibrosis in mixed, 
HCV and NAFLD patient groups.28
Protein Fingerprint biomarkers
During extracellular matrix (ECM) turnover, proteo-
lytically cleaved matrix degradation fragments or 
neoepitopes, are released into the systemic circulation. 
Cleavage of each ECM protein by specific MMPs gener-
ates a unique neoepitope. These neoepitopes are more 
accurate diagnostic and prognostic markers for indi-
vidual fibroproliferative diseases than their protein of 
origin. These novel serum biomarkers have been shown 
to identify patients with progressive fibrosis and permit 
monitoring of the response to antifibrotic therapy,29 and 
also correlate with portal hypertension in patients with 
cirrhosis.30
TE (Fibroscan)
TE is a non- invasive method for assessing liver fibrosis. 
Mild amplitude and low frequency vibrations (50 Hz) are 
transmitted to the liver tissue, inducing an elastic shear 
wave that propagates through the underlying liver tissue. 
The velocity of the wave is directly related to tissue stiff-
ness, considered as a surrogate of the amount of fibrotic 
tissue. This is expressed as a numerical value in kilopascals 
(kPa). It is reliable, reproducible with high intraobserver 
and interobserver agreement and has been validated in 
most causes of chronic liver disease31
Chronic Liver Disease Quality of Life Questionnaire
The Chronic Liver Disease Quality of Life Questionnaire 
(CLDQ) is a liver- specific questionnaire for measuring 
HRQoL in participants with chronic liver disease. It is self- 
administered, takes approximately 10 min to complete 
and is designed to reflect the 2 weeks prior to testing. 
If necessary, participants can request help to complete 
this.32
It includes 29 items divided into 6 quality of life 
domains: Abdominal symptoms, Fatigue, Systemic symp-
toms, Activity, Emotional function and Worry. These items 
are ranked on a 1–7 scale, providing a possible range of 
scores from 29 (worst quality of life) to 203 (best quality 
of life). The construct validity of the CLDQ was supported 
by a strong correlation with participant’s global rating 
scores. It has been shown to be valid and has good test–
retest reliability.33–35
UKELD score
The UKELD score is readily performed incorpo-
rating routine biochemical and haematological indices 
including bilirubin, albumin, alanine transaminase (ALT) 
and International Normalised Ratio (INR). The UKELD 
score was developed by the UK Liver Transplant Units to 
predict transplant waiting list mortality.36
The score uses the parameters of Bilirubin (Bil), INR, 




MRI and MR spectroscopy
MRI and spectroscopy (MRS) provide methods for the 
non- invasive assessment of liver microstructure and func-
tion. MRI allows for imaging biomarkers to be determined 
using LiverMultiScan.37 Tissue microstructure will be 
investigated using clinically validated metrics. Fibrosis will 
be assessed by cT1, iron content with T2* and the amount 
of fat in the liver using proton density fat fraction. Organic 
phosphorus in the liver can be quantified with Phospho-
rus- 31 (31P) MRS38 a more explorative technique. Using 
31P MRS energy metabolism may be investigated via ATP 
levels and cell membrane integrity by measuring precur-
sors and degradation products. The paired imaging of this 
study allows for the current utility of MRI to assess disease 
progression and treatment response to be evaluated
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MRI data collected is exploratory and will be according 
to subgroup analysis: the only planned subgroup analysis 
is to present the primary outcome for the RCT by disease 
aetiology (ALD, NAFLD, other). MRI is performed 
at index visit 2 (or within 7 days) and again at primary 
outcome time point of 90days (±7).
Sample size/power calculation
To detect a difference in the baseline to 90- day change 
in MELD score of 1 SD using a two- sided, two- sample test 
with a 5% level of significance, a sample size of 23 per 
group to detect the same level of difference with 90% 
power is required. All analyses will be carried out on an 
intention to treat basis, retaining participants in their 
randomised treatment groups irrespective of the treat-
ment received. Adverse event (AE) data will be presented 
by treatment received.
The number of participants who do not adhere to the 
protocol is expected to be low. All protocol violations and 
ineligible participants will be recorded.
Recruitment
Identification of potential patients
Potential participants will be identified by their usual 
direct healthcare team. The treating physician will either 
introduce the individual to the trial team or ask permis-
sion for the trial team to contact them; this could be done 
through a dedicated invitation letter or a telephone call. 
The participant information sheet will be provided and 
there will be an opportunity to ask questions. If they agree, 
a further visit will be scheduled to discuss trial enrolment. 
This will take place no less than 24 hours later.
Randomisation
Following confirmation of the participant meeting the 
eligibility criteria, a delegated member of the research 
team will enter minimal information (participant id, and 
aetiology) into an online randomisation system, produced 
for the study by Edinburgh Clinical Trials Unit to deter-
mine the treatment allocation. At randomisation, patients 
will be allocated a unique patient trial number and sched-
uled for treatment and follow- up visits as detailed in the 
trial schedule.
Allocation
Participants will be assigned to receive either standard 
medical care or to receive a fresh dose of autologous 
MDMs at the maximum achievable dose, in a 1:1 ratio 
based on a minimisation algorithm using the key variable 
aetiology of disease (ALD, NAFLD, other.) To ensure the 
allocation is random, participants will be assigned to the 
group which minimises the imbalance with probability 
0.8. If a participant falls into two or more strata, then the 
dominant aetiology (as determined by treating physician) 
will be used.
Blinding
Due to the nature of the intervention neither partici-
pants nor staff can be blinded to allocation of treatment. 
For some of the additional secondary outcomes we will 
maintain blinding of external assessors including those 
processing samples for ELF and protein fingerprint 
markers. Similarly, there is blinding of MRI physicists and 
external validation companies responsible for experi-
mental MRI interpretation.
Data collection
The case report form (CRF) will be completed at set time 
points as per trial schedule. The CRF will be completed by 
the investigator or an authorised member of the research 
team (as delegated on the Site Signature and Delegation 
Log). The exception is the serious AE Form which must 
be signed by the investigator.
Data reported in each form should be consistent with 
the source data or the discrepancies should be explained. 
If information is not known, this must be clearly indicated 
in the form.
Completed CRFs submitted to the clinical research 
facility will be reviewed by the trial coordinator. The data 
will be entered into an electronic database by designated 
members of the trial team.
Data management
The following personal data will be collected as part 
of the research: name, date of birth and CHI numbers 
(Community Health Index; a unique is a 10- character 
numeric identifier, allocated to each patient on first regis-
tration with the NHS system in Scotland). Personal data 
will be stored in locked cabinets by the research team at 
the clinical research facilities at each site. Personal data 
will be stored for 30 years in keeping with the blood safety 
and quality regulations. The University of Edinburgh and 
NHS Lothian are joint data controllers along with any 
other entities involved in delivering the study that may be 
a data controller in accordance with applicable laws.
All investigators and study site staff involved with this 
study must comply with the requirements of the appro-
priate data protection legislation (including where appli-
cable the general data protection regulation regarding 
the collection, storage, processing and disclosure of 
personal information. Access to personal information 
will be restricted to individuals from the research team 
treating the participants, representatives of the spon-
sor(s) and representatives of regulatory authorities.
Study data will be collected and managed using 
Research Electronic Data Capture (REDCap) electronic 
data capture tools hosted at The University of Edinburgh. 
REDCap39 is a secure, web- based application designed 
to support data capture for research studies, providing: 
an intuitive interface for validated data entry; audit trails 
for tracking data manipulation and export procedures; 
automated export procedures for seamless data down-
loads to common statistical packages; and procedures for 
importing data from external sources.
Published results will not contain any personal data that 
could allow identification of individual participants.
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Statistical analysis plan
The baseline to 90- day change in MELD score will be 
compared in the two treatment arms using a two- sample 
t- test or non- parametric equivalent as appropriate. MELD 
scores calculated for each participant throughout the trial 
will be used to calculate an area under the curve (AUC) 
and this will be compared across the groups using a two- 
sample t- test or non- parametric equivalent as appropriate. 
In the event of varying durations in the trial follow- up, the 
average AUC per month will be used so that all partici-
pants have a comparable measurement.
Changes in secondary outcome measures (ELF score 
liver stiffness, CLDQ score, transplant- free survival, 
number of clinical events, UKELD score, blood parame-
ters (bilirubin, albumin, ALT, INR)) over the 1- year study 
period will be presented graphically by dose. Similarly, 
these results will used to calculate an AUC for each partic-
ipant and will be compared across the groups using a two- 
sample t- test or non- parametric equivalent as appropriate.
The only planned subgroup analysis is to present the 
primary outcome by disease aetiology (ALD, NAFLD, 
other). Primary data analysis will be conducted on partic-
ipants who receive a single infusion versus control; the 
primary analysis will then be repeated to include those 
subjects who receive more than one infusion (three indi-
viduals). There are no plans for an interim analysis.
Data monitoring
The trial will be coordinated by a project management 
group, consisting of the grant holders (chief investigator 
and principal investigator in Edinburgh), a trial manager 
and coordinating nurse.
The trial manager will oversee the study and will be 
accountable to the chief investigator. The trial manager, 
or an authorised member of the research team, will be 
responsible for checking the CRFs for completeness, 
plausibility and consistency. Any queries will be resolved 
by the Investigator or delegated member of the trial team. 
A Delegation log will be prepared detailing the responsi-
bilities of each member of staff working on the trial.
Safety assessments
The investigator is responsible for the detection and 
documentation of events meeting the criteria and defini-
tions detailed within the protocol (available on request). 
Full details of contraindications and side effects that have 
been reported following administration of the IMP can 
be found in the relevant investigator’s brochure.
Participants will be instructed to contact their Investi-
gator at any time after consenting to join the trial if any 
symptoms develop. All AEs that occur after joining the 
trial must be reported in detail in the CRF or AE form. 
In the case of an AE, the investigator should initiate 
the appropriate treatment according to their medical 
judgement. Any AE events still present on day 360 will 
be confirmed and recorded as ‘ongoing’ in the CRF. If 
appropriate, these should be handed over to the partici-
pants’ general practitioner or direct care team.
The ACCORD Research Governance and QA Office is 
responsible for pharmacovigilance reporting on behalf 
of the cosponsors (University of Edinburgh and NHS 
Lothian).
The ACCORD Research Governance and QA Office 
has a legal responsibility to notify the regulatory compe-
tent authority and relevant ethics committee (Research 
Ethics Committee (REC) that approved the trial). Fatal or 
life threatening Suspected Unexpected Serious Adverse 
Reactions (SUSARs) will be reported no later than seven 
calendar days and all other SUSARs will be reported no 
later than 15 calendar days after ACCORD is first aware 
of the reaction.
ACCORD will inform investigators at participating sites 
of all SUSARs and any other arising safety information.
An annual safety report/development safety update 
Report will be submitted, by ACCORD, to the regulatory 
authorities and RECs listing all SARs and SUSARs.
Monitoring and oversight
An ACCORD clinical trials monitor, or an appointed 
monitor will visit the investigator site prior to the start of 
the study and during the course of the study if required, 
in accordance with the monitoring plan if required. Risk 
assessment will determine if audit, by the ACCORD QA 
group, is required. Details will be captured in an audit 
plan.
DISCUSSION
MATCH is an RCT designed to identify whether there is 
a measurable improvement in MELD score and also in 
relevant secondary clinical outcomes, HRQoL and non- 
invasive biomarkers following autologous macrophage 
therapy. It builds on the safety and feasibility assessment 
of the earlier phase I trial. Recent Food and Drug Admin-
istration (FDA) guidance on development of treatments 
for cirrhosis has indicated there are no acceptable surro-
gate endpoints (eg, histological improvement) so our 
focus in this study is on clinically meaningful assessments 
such as liver function, survival and HRQoL rather than 
liver biopsy.
Previous clinical trials using MSCs across a range of 
aetiologies of liver disease have yielded mixed results. In 
trials which reported efficacy, the apparent benefit was 
transient, with no long- term improvement.40 41
One important rationale for using macrophages relates 
to the lack of efficacy of haematopoetic stem cells,42 
inherent challenges of using transplanted hepatocytes, 
and potential risk of introducing transplanted hepato-
cytes MSCs into a hostile host niche. Previous trials have 
demonstrated concerns around cellular engraftment and 
expansive potential of such approaches.
Preclinical studies undertaken by our group have 
administered macrophages via the portal vein, tail vein 
or intrasplenic route, but in our phase 1 trial we success-
fully used peripheral intravenous infusion which is safer 
and more convenient. While there is no cell- tracking 
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technique used in this trial to assess cell engraftment/
durability, animal models and human case reports suggest 
that macrophages infused via either peripheral or central 
veins will transiently pass through the lungs, before 
engrafting in the liver and spleen.21 However, hepatic 
artery or portal venous administration are considerably 
more invasive, with concerns regarding risk of bleeding 
and vessel injury,43 and problems related to reversal of 
portal flow/porto- systemic shunting or splanchnic vessel 
thrombosis.14
Through this trial, we aim to add to the collective 
knowledge of this potential new therapeutic modality for 
liver disease in this patient population who currently have 
limited treatment options. If effective, autologous macro-
phage cell therapy will improve clinical outcomes and 
enhance HRQoL in people with cirrhosis.
Following initial trial results, we expect that a further 
extended study will be necessary to determine longer- 
term safety and the durability of treatment responses. 
Moreover, it is not yet clear whether patients may require 
repeat treatments to maximise efficacy.
We hope that this initial phase II trial will provide 
robust evidence to support and inform future trial design.
ETHICS AND DISSEMINATION
The trial will be conducted according to the ethical prin-
ciples of the Declaration of Helsinki 2013 and has been 
approved by Scotland A Research Ethics Committee 
(reference 15/SS/0121), NHS Lothian Research and 
Development department and the MHRA- UK. Good 
Clinical Practice regulations will be followed and written 
informed consent will be obtained from all participants. 
Results will be disseminated through peer- reviewed publi-
cations, presented at conferences and published on  Clin-
icalTrials. gov. Ownership of the data arising from this 
study resides with the study team and their respective 
employers. The study team will follow the International 
Committee of Journal Editors guidelines. Requests for 
data access should be sent to the corresponding author 
(ORCID: 0000- 0001- 8368- 1478).
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